secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vivos Therapeutics, Inc. (VVOS)
CIK:        0001716166
Form:       8-K
Filed at:   2025-04-17T23:59:59+00:00
Accession:  0001641172-25-005165
Event type: m_and_a
Sentiment:  positive
Materiality: 0.75
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Vivos Therapeutics signs $9M deal to acquire Nevada sleep center operator SCN
-----------------------------------------------------------------------------

- Total consideration up to $9M: $6M cash + $1.5M stock at closing + $1.5M stock earn-out.
- SCN sees ~3,000 new patients/month; annual revenue in high seven figures; 7 locations in Nevada.
- Close expected Q2/Q3 2025, subject to financing, audit, and customary conditions; no shareholder vote needed.
- Employment agreement for Dr. Rachakonda includes $400K salary and board observation right; New Seneca Partners assisted.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1716166/000164117225005165/0001641172-25-005165-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1716166/000164117225005165/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001641172-25-005165

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer